Rapid induction to extended-release buprenorphine 300-mg injection feasible and well tolerated for those using fentanyl
Predictors include history of overdose, higher opioid dose, three or more prescribers, any mental health diagnosis
Higher 90-day treatment retention rates seen with no higher risk for overdose
Implementation of opioid use disorder screening does not increase percentage of patients with new diagnosis
Opioid crisis hitting those without college education the hardest
Extended-release buprenorphine not cost-effective when transmucosal buprenorphine is available for treatment of OUD
Receipt of physical therapy and chiropractic care was low overall and lower across racial, ethnic minorities
Regardless of prognosis, panel deemed it appropriate to continue opioids, increase monitoring, and avoid opioid tapering
Court is asking the parties to show whether bankruptcy law allows for a blanket shield from all litigation by opioid victims
Medications for OUD more likely for those with severe versus mild past-year OUD, receiving substance use treatment via telehealth